OPKO Health, Inc, a multinational biopharmaceutical and diagnostics company that is developing a novel long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD), will hold a conference call and webcast on Tuesday, June 24, 2014.
During the call, OPKO Biologics management will discuss data from the company's advanced phase 2 trial of hGH-CTP in growth hormone deficient pediatric subjects. The pharmacokinetic and pharmacodynamics portion of the results will also be presented at a poster presentation on the prior Monday afternoon from 2:00 p.m. to 4:00 p.m. during the International Congress of Endocrinology and Endocrine Society's Annual Meeting and Expo at the McCormick Place West in Chicago, Illinois. The poster is titled "Pharmacokinetics and Pharmacodynamics Profile of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency". An additional poster titled "Production and Characterisation of MOD-4023, a LONG Acting Growth Hormone and Supporting Clinical and Commercial Drug Product Supply" will be presented in parallel.
The data to be discussed during the call will include six month height velocity and safety data from the company's phase 2 trial, which is a one year dose finding study administering hGH-CTP to growth hormone deficient children once a week using daily hGH as a comparator arm. These data affirmed that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed hGH, further validating the optimal dose and dosing regimen for the upcoming phase 3 trial in paediatric patients. In addition, hGH-CTP demonstrated a very good safety and tolerability profile in this ongoing study, with no unexpected adverse events.
OPKO will hold a conference call on Tuesday, June 24, 2014 at 8:30 a.m. The dial-in numbers are 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers. A webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.opko.com.
After the webcast, the call will remain available on the OPKO website, www.opko.com, for 30 days.
In June 2013, OPKO initiated a pivotal phase 3 clinical trial in adults of its proprietary long-acting version of hGH-CTP. hGH-CTP has been awarded orphan drug designation in the US and Europe for both adults and children with growth hormone deficiency.